Suggested remit - To appraise the clinical and cost effectiveness of dapagliflozin within its marketing authorisation for treating adults with chronic heart failure with reduced ejection fraction.
Status In progress
Process STA 2018
ID number 1656

Provisional Schedule

Committee meeting: 1 12 November 2020

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors AstraZeneca (dapagliflozin)
Others Department of Health and Social Care
  NHS England
  NHS Bracknell and Ascot CCG
  NHS South Devon and Torbay CCG
  Welsh Government
Patient carer groups Arrhythmia Alliance
  Atrial Fibrillation Association
  Blood Pressure UK
  British Cardiac Patients Association
  Cardiomyopathy UK
  Cardiovascular Care Partnership
  Muslim Council of Britain
  Network of Sikh Organisations
  Pumping Marvellous Foundation
  Somerville Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups British and Irish Hypertension Society
  British Association for Nursing in Cardiovascular Care
  British Cardiovascular Society
  British Geriatrics Society
  British Heart Foundation
  British Heart Rhythm Society
  British Nuclear Cardiology Society
  British Society for Heart Failure
  British Society of Cardiovascular Imaging
  King’s Fund
  National Heart and Lung Institute
  Royal College of Emergency Medicine
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Cardiological Science & Technology
  Society for Vascular Nurses
  Society for Vascular Technology
  UK Clinical Pharmacy Association
  Vascular Society of Great Britain and Ireland


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord (bisoprolol, captopril, enalapril, eplerenone, hydralazine, irbesartan, ivabradine, lisinopril, losartan, nebivolol, olmesartan, perindopril, ramipril, spironolactone, telmisartan, valsartan)
  Advanz (hydralazine, nebivolol)
  Aspire (eplerenone, ivabradine)
  AstraZeneca (lisinopril)
  Aurobindo pharma (bisoprolol, candesartan, carvedilol, enalapril, irbesartan, lisinopril, losartan, nebivolol, olmesartan, perindopril, quinapril, ramipril, valsartan)
  Boehringer Ingelheim (telmisartan)
  Brown and Burk (irbesartan, lisinopril, losartan, ramipril)
  Consilient health (candesartan, eplerenone, irbesartan, losartan, perindopril, telmisartan)
  Daiichi Sankyo (olmesartan)
  Dexcel pharma (enalapril, losartan, valsartan)
  Glenmark pharma (nebivolol, olmesartan, perindopril, telmisartan)
  Lupin Healthcare (irbesartan, quinapril)
  Martindale pharma (captopril)
  Menarini (nebivolol)
  Merck Sharp & Dohme (bisoprolol, enalapril, losartan)
  Mylan (bisoprolol, candesartan, enalapril, eplerenone, eprosartan, hydralazine, lisinopril, losartan, olmesartan, perindopril, valsartan)
  Novartis (sacubitril valsartan, valsartan)
  Pfizer (eplerenone, quinapril, spironolactone)
  Sandoz (bisoprolol, candesartan, losartan, ramipril)
  Sanofi (irbesartan, ramipril, spironolactone)
  Servier laboratories (arginine, ivabradine, perindopril)
  Takeda (azilsartan, candesartan)
  Thame laboratories (captopril)
  Wockhardt (ramipril)
  Zentiva (eplerenone, irbesartan, ivabradine, ramipril)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Society for Cardiovascular Research
  Cardiac and Cardiology Research Dept, Barts
  Circulation Foundation
  Cochrane Heart Group
  Cochrane Hypertension Group
  Cochrane Vascular
  European Council for Cardiovascular Research
  Genomics England
  Heart Research UK
  MRC Clinical Trials Unit
  National Centre for Cardiovascular Preventions and Outcomes
  National Institute for Health Research
  Wellcome Trust


Key events during the development of the guidance:

Date Update
02 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
13 March 2020 Invitation to participate
13 March 2020 In progress, In progress
20 November 2019 - 18 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance